Enterprise Ireland’s support of Aerogen began with feasibility funding in 1997, when John Power founded the company in Galway, and has been consistent ever since.
Having started in Galway in 1997, Aerogen has grown to the point where its innovative aerosol drug delivery solution has reached 75 markets around the world.
In every international market Aerogen is active in, Enterprise Ireland was its first port of call in terms of learning about those markets and accessing key contacts, according to CEO John Power.
Most recently, it worked closely with Enterprise Ireland’s overseas office in Dubai where Aerogen is setting up its own office to serve the Middle East.
“We worked with Enterprise Ireland’s people on the ground in Germany, France and the Nordic countries for years and we still use its overseas offices all over the world”
“We have found in every market that you will not get a better national industrial support group for exporting than we have with Enterprise Ireland. The people on the ground always go the extra mile and are contactable day and night.”
As a company, Aerogen is heavily focused on research and development (R&D). Supports from Enterprise Ireland have allowed the company to continue to innovate and develop new clinical products – which would probably have been too risky to undertake alone, notes Power.
“Our aerosol drug delivery solution made its name in intensive care units around the world. While this continues to be a strong focus, we have since developed products for use in emergency departments and are working on products designed for operating theatres.”
The agency has also been hugely supportive when it comes to attendance at trade shows, adds Power – for example Aerogen is just back from the Arab Health event, where it shared a booth with Enterprise Ireland and other Irish companies.
